Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06033248 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Using Urine Samples to Identify Lung Cancer

StatusRecruiting
PhaseNot specified
Started2023-08-24
View on ClinicalTrials.gov ↗
The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that are trained to detect (by smell) different chemicals in urine. Studies show that people with lung cancer have unique chemicals in their urine that are not present in people without lung cancer, and researchers think these chemicals can be used to identify people with lung cancer without the need for invasive procedures (like biopsy).

Amendment history 2 changes detected by DataLookout

2026-09-16
critical
Primary completion pushed: 2026-08 → 2027-08
2026-09-16
minor
Completion pushed: 2026-08 → 2027-08
Trial Details
NCT Number NCT06033248
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: EARLY Labs
Conditions Non Small Cell Lung Cancer
Enrollment 210 participants
Start Date 2023-08-24
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-15